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Previous research on functional outcome in bipolar disorder (BD) has uncovered various factors that exacerbate psychosocial
disability over the course of illness, including genetics, illness severity, stress, anxiety, and cognitive impairment. This paper
presents an integrated view of these ﬁndings that accounts for the precipitous decline in psychosocial functioning after illness
onset. The proposed model highlights a number of reciprocal pathways among previously studied factors that trap people in a
powerful cycle of ailing forces. The paper discusses implications to patient care as well as the larger social changes required for
shifting the functional trajectory of people with BD from psychosocial decline to growth.
1.Introduction
Psychosocial functioning in bipolar disorder (BD) runs the
full gamut of human potential. Whereas some people with
BD accomplish historical landmarks in human achievement
[1–3], others experience signiﬁcant diﬃculties in managing
tasksofdailyliving[4].Theremarkablefunctionalvariability
in BD highlights an inherent prognostic complexity [5–7],
which is not immediately evident in the diagnosis [8].
Many studies have illuminated various aspects of illness pro-
gression in BD [9–11], yet signiﬁcant improvement to func-
tional outcome may require further theoretical and clinical
advancement [12].
The astounding functional diﬀerences among people
with BD present one of the toughest challenges to this eﬀort,
as these emerge across the entire spectrum of human de-
velopment [7, 13–16]. Early emotional abnormalities and
poor premorbid functioning tend to occur in BD [17–19];
however, adequate psychosocial adjustment prior to the ﬁrst
manic episode is also common [20–22]. Furthermore, after
illness onset, many people with BD regain psychosocial fun-
ctioning [13, 23], yet others suﬀer inordinate functional
decline, which progresses from a state of psychosocial ad-
justment to a state of disability [23, 24]. The latter group is
of particular interest to clinical research. Understanding the
nature of the sometimes dysfunctional trajectory of BD may
help to diminish it, and thereby reduce suﬀering and cost.
This paper examines the strongest predictors of func-
tional outcome in BD, which have been separately summa-
rized in multiple previous reviews. In this regard, the paper
does not aim to provide a comprehensive review of studies
linking each of the factors under discussion to psychosocial
functioning in BD. Instead, it oﬀers an integrated view on
previously reviewed ﬁndings and discusses potential im-
plications for prevention and patient care.
2.DirectEffectsof CognitiveDysfunction
Cognitive impairment is among the strongest predictors
of psychosocial disability in BD [6, 25]. Cross-sectional
studies, now summarized in several comprehensive reviews
and meta-analyses, indicate that cognitive deﬁcits often per-
sist into periods of euthymia [26–28], especially in people
who suﬀer from marked psychosocial impairment during
aﬀective remission [29, 30]. The co-occurrence of cognitive
and psychosocial impairment in the absence of mood symp-
toms advanced hypotheses about the ill eﬀects of cognitive
dysfunction on psychosocial adjustment in BD [31, 32].
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to nonexperimental evidence, this hypothesis gained con-
siderable support from longitudinal studies that employed
cognitive measures to predict long-term functional outcome
in BD [13, 25, 33–37]. Longitudinal predictions that account
for the confounding eﬀects of mood symptoms suggest that
cognitive impairment diminishes psychosocial functioning
in BD [13, 25, 34].
In a broad view, the logic behind linking cognitive
impairment to psychosocial disability in BD may parallel
the reasoning that has created this association in dementia.
The resemblance between cognitive symptoms of BD and
those of dementia often goes unnoticed, because the degree
of functional limitation can diﬀer substantially between
these disorders. Whereas the large contribution of cognitive
impairment to psychosocial decline is widely recognized in
dementia, the eﬀects of cognitive impairment on functional
outcome in BD may be more selective and subtle. Relative
to that in dementia, the cognitive impairment in BD is
milder, and the disruption to psychosocial functioning is
less dramatic; however, the basic notion linking cognitive
impairment to psychosocial disability is similar in nature. In
some respects, people with BD who suﬀer from signiﬁcant
functional disability during euthymia may experience the
illness as an attenuated or subclinical form of dementia. This
view is supported by evidence that cognitive impairment in
BD tends to be progressive over the course of illness [38–40]
and correlates with psychosocial decline [41].
Cognitive impairment is milder in BD than in certain
forms of dementia (e.g., Alzheimer’s type) partly because
it is not characterized by a severe amnesic syndrome [42].
The core dysfunction in BD during euthymia is executive in
nature [43, 44]. Some researchers have even suggested that
deﬁcits in learning and memory are probably secondary to
executive impairment [45]. The absence of a severe amnesic
syndrome spares basic learning capacities and psychosocial
functions; however, the executive dysfunction in BD may be
signiﬁcant enough to quickly limit the utility of preserved
functions, particularly as task complexity increases [7, 32].
In BD [46] and in geriatric populations generally [47–49],
disturbances in executive functioning have been tied to
diﬃculties in accomplishing tasks of daily living. Studies also
indicate that executive dysfunction in BD predicts poorer
academic performance [50] ,w o r s ev o c a t i o n a lo u t c o m e s[ 25,
51], reduced social adjustment [52], and diminished quality
of life [53, 54].
Thus, although cognitive impairment in BD is not com-
pletely incapacitating, the balance of the data suggests that
it generates signiﬁcant disruption to social and vocational
adjustment [6, 13, 55, 56]. In other words, people with BD
whosuﬀersigniﬁcantexecutiveimpairmentduringeuthymia
may not need custodial care, but they probably struggle to
ﬁtintomainstreamenvironments,wherefunctionalexpecta-
tions are typically set for the cognitively intact.
3.DirectEffectsof IllnessSeverity
Illness severity is another strong predictor of psychosocial
disability in BD [57]. Younger age of onset [58], longer
duration of mood episodes [6], higher number of psychiatric
hospitalizations [51], lingering residual symptoms [59, 60],
psychosis [61], and substance use disorders [62, 63]a l l
predict greater psychosocial dysfunction in BD.
The argument for a direct impact of illness severity
on psychosocial functioning in BD probably provides the
most intuitively appealing explanation for the correlation
between these two variables. Younger age of onset disrupts
psychosocial development at an earlier stage, altering the
trajectory of educational, professional, and interpersonal
growth [64, 65]. In addition, the break of psychiatric illness
early in life likely carries deleterious eﬀects on identity
development [66]. Coupled with the stigma associated with
mental illness generally and BD in particular [66–71],
these internal eﬀects may hamper eﬀorts to achieve social
adjustment [69, 71]. Further challenge to these eﬀorts comes
from recurrent mood episodes and frequent hospitalizations
over the course of illness, imposing inconsistency to edu-
cational and vocational pursuits and repeated disruption
to interpersonal engagement [5, 66, 68, 72–74]. Lingering
residual symptoms between mood episodes impede eﬀorts
to reengage with psychosocial demand [25, 30, 33], and
thereby make functional recovery after hospital discharge
more challenging [75]. Finally, episodes of psychosis and
chronic substance misuse contribute to an erratic course of
development [61, 62]. The emotional and behavioral lack of
control associated with substance use and psychosis dimin-
ishes the likelihood of obtaining psychosocial adjustment
later in life [61, 62]. Taken together, all of these factors carry
direct eﬀects on psychosocial functioning and development
in BD.
4. The LinkbetweenCognitiveDysfunction
andIllnessSeverity
The direct impact of cognitive impairment and illness sever-
ity on psychosocial functioning in BD may be compounded
by the potential synergy between these factors. An increasing
volume of studies indicate a robust association between
illness severity and cognitive functioning in BD [40, 76, 77].
In particular, the number of mood episodes negatively cor-
relates with cognitive functioning in a number of domains,
including executive functioning and verbal memory [78].
In addition, cognitive dysfunction in BD is associated with
the number of hospitalizations and the duration of mood
episodes [77, 79].These studies advanced the hypothesis that
a more severe course of illness leads to progressive cognitive
decline in BD in a process that may involve neurodegen-
eration [76, 80].
The neurodegenerative hypothesis holds that chronic
mood instability generates physiological stress with neuro-
toxic eﬀects, leading to neurological damage and cognitive
decline over the course of illness [76, 80]. Within this model,
Kapczinski et al. [80] applied the notion of “allostatic load”
(AL) to BD. AL generally refers to the “wear and tear”
of biological systems that occurs during physiological adjust-
ment to stress, whereby this process becomes distorted
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captures the biological toll of adaptation to excessive stress
[81]. The higher rates of morbidity and mortality found
in people with BD due to medical conditions not directly
related to their psychiatric disorder, such as cardiovascular
disease, obesity, diabetes mellitus, and metabolic syndrome
[82–84], evince the deleterious physiological eﬀects of stress
in BD [85, 86]. Evidence for possible eﬀects of stress on
the brain comes from neuroimaging studies that found
morphological abnormalities in BD [87]. In a recent review,
Arnone et al. [87] concluded that BD is associated with
whole brain and prefrontal lobe volume reductions, along
with volume increases of the lateral ventricles. There is
evidencethatthese and relatedbrainabnormalities inBD are
associated with both cognitive [88] and psychosocial decline
[89]. Taken together, these studies suggest a stress-related
cognitive, neurological, and psychosocial decline in people
with BD who suﬀer from a more severe course of illness.
From a broader perspective, the link itself—between
illness severity and neurocognitive decline—may aggravate
the direct eﬀects that each of these factors have on psy-
chosocial functioning in BD. Thus, a more severe course
of illness reduces psychosocial functioning in BD and
simultaneously decreases neurocognitive functioning, which
then also directly lowers functional outcomes. Thus, the two
factors that have the strongest direct eﬀect on psychosocial
functioning in BD may be looped together in a way that
accelerates functional decline.
5.Anxiety
BDhasaparticularlyhighrateofcomorbidanxietydisorders
estimated at over 50% in several studies [90, 91]. Intense
a n x i e t yi nB Dp r e d i c t sam o r es e v e r ec o u r s eo fi l l n e s sa n d
poor prognosis [92, 93]. A number of studies found that
people with BD who suﬀer chronic anxiety tend to have
a younger age of onset, longer and more frequent mood
episodes [94, 95], higher prevalence of substance use disor-
ders [96], decreased response to lithium and anticonvulsant
medication [92, 94, 97], and increased suicidal ideation and
attempts [98]. Coupled with illness severity, comorbid anx-
iety disorders strengthen the prediction of poor functional
outcome in BD, as indicated by lower GAF scores, decreased
social role functioning, poorer quality of life, and minimal
employment [95, 99, 100].
Anxiety, which may reﬂect a natural emotional reaction
to the instability that inheres in severe psychiatric disorders,
may also exacerbate illness severity and functional deterio-
ration through relatively underinvestigated pathways. One
such pathway may involve the potentially negative impact
of anxiety on cognitive functioning [101]. High levels of
anxiety can signiﬁcantly compromise attentional control
and decision making even in nonpsychiatric populations
[102, 103]. Well-designed studies indicate that neuropsy-
chological test scores, across 6 cognitive domains, tend to
be particularly sensitive to hypothalamic-pituitary-adrenal
(HPA) axis dysregulation and elevated levels of cortisol
[103, 104]. The HPA axis in BD can be dysregulated across
all clinical states, including euthymia [105, 106], and may
aﬀect cognitive functioning. Thus, HPA axis dysregulation
can lead to debilitating cognitive impairment not only
through the neurotoxic eﬀects of inordinate allostatic loads,
but more directly through excessive sympathetic arousal,
triggered by the cognitive challenges of daily living. In short,
it seems feasible to hypothesize that acute anxiety may
compromise cognition in BD. Anxiety can potentially make
baseline cognitive impairment circumstantially more acute
and thereby further decrease functional abilities.
Another pathway in which anxiety may compromise
psychosocial function in BD could be related more specif-
ically to the encounter between cognitive impairment and
demand in psychosocial contexts. This encounter may pro-
duce anxiety, especially when the person is unable to meet
expectations in highly visible social circumstances. Thus,
while anxiety compromises cognition, cognitive challenges
in a cognitively compromised state can trigger anxiety. Even
in nonpsychiatric populations, cognitive challenges signiﬁ-
cantlyincreaseanxietyandphysiologicalarousal[101].Phys-
iological anxiety in nonpsychiatric subjects increases during
cognitive testing and rises even further when subjects make
errors [107]. These eﬀects are more intense in people who
suﬀer from mental illness or substance use disorders, even
during remission or abstinence [108, 109].
Since the most common behavioral reaction to anxiety
is avoidance [110], people with BD who experience cogni-
tive impairment may tend to withdraw from psychosocial
demands that evoke anxiety to decrease their experiences of
social failure. More broadly, the encounter between cognitive
impairment and demand in daily life can create anxiety
that exacerbates cognitive deﬁcits, limits functional ability,
reduces motivation, and leads to avoidance of psychosocial
engagement. In schizophrenia research, several studies sug-
gest that an avoidant coping style mediates the link between
neurocognitive impairment and psychosocial functioning
[111, 112]. Although there is little direct evidence that psy-
chosocial avoidance plays a similar role in people with BD,
this hypothesis remains viable, given the similarities between
cognitive impairment in BD and schizophrenia [111, 113].
In summary, the interplay between anxiety and cognitive
impairment may further limit functional capacities and
exacerbate psychosocial decline in BD.
6. Diathesis-Stress
Various diathesis-stress [86, 114]a n dr e l a t e dm o d e l s[ 115,
116] in BD research highlight the interactions between
genetics and environmental stress as important predictors of
illness onset and severity. These models broadly hold that
cumulative environmental stressors trigger a person’s genetic
predisposition to experience mood disturbance and aﬀect
the progression of the illness after onset [117, 118]. In a
recent review, Bender and Alloy [114] examined evidence
for three of these models—the kindling hypothesis of illness
progression in BD [119], the behavioral approach system
(BAS) dysregulation model [120], and the social rhythm
disruption (SRD) model [121].4 Depression Research and Treatment
The kindling hypothesis asserts that major stressful life
events (SLEs) are required to trigger initial episodes in BD,
but then, subsequent episodes become progressively uncou-
pled from stressors, to the point that future episodes may
appear to occur independent of life stress. The kindling
model is supported by multiple studies that found major
SLEs occurring particularly in the year before the ﬁrst ep-
isode of mood disturbance [114, 115, 121]o re a r l yo ni n
the course of illness [122]. However, Bender and Alloy [114]
found that many of these studies were methodologically
ﬂawed and oﬀer only limited support to the widely cited
kindling hypothesis.
The BAS dysregulation model is based on research show-
ing that behavior is regulated by goals and rewards (when
faced with goal-related cues) and a behavioral inhibition
system (BIS) that triggers avoidance when a person is faced
with cues related to threat or punishment [114, 120]. There
is some evidence that in persons with BD, the BAS may be
hyper-sensitive such that goal-related cues may trigger hy-
pomanic behavior, while threat-related cues may trigger de-
pression [114, 120].
The SRD model of diathesis stress is supported by
several studies ﬁnding that SLEs, in combination with ge-
netic diﬀerences, predict manic and depressive symptom
recurrence [123] and delay in functional recovery [124]
over the course of illness. On the side of genetics, Hosang
et al. [125] found that for the worst depressive episodes in
BD, stressful life events (SLEs) were signiﬁcantly moder-
ated by BDNF genotype—Val66Met polymorphism. On the
side of environmental stress, diminished perceived social
support and psychosocial stress appear to be particularly
predictive of mood instability in BD [123, 126–128]. In
this regard, there is evidence that SRD and disruption to
the attainment of psychosocial goals are associated with the
number of reported manic episodes [121, 129]. In addition,
social rhythm irregularity predicts time to aﬀective relapse
[121], and there is some evidence that persons diagnosed
with BD experience higher numbers of SLEs and greater
SRD than people without psychiatric illness [130]. Taken
together, these studies point to the possible development
of a reciprocal loop between SRD and mood symptoms, in
which SRD aggravates the genetic propensity toward mood
disturbance, and mood symptoms in turn exacerbate SRD.
In sum, these ﬁndings suggest that genetics carry an
important inﬂuence on illness severity in BD, that SRD is
a particularly destabilizing source of stress for people with
a genetic predisposition toward BD, and that people with
BD experience more psychosocial stress than people without
mentalillness.Thesefactorsmaybecentraltounderstanding
functional decline in BD. SRD alone, by deﬁnition, disrupts
psychosocial functioning. Its eﬀects in BD, however, might
be compounded by the association between SRD and the
recurrence of genetically triggered mood instability, which
imposes a powerful and direct impediment to psychosocial
development.
7.TheIntegratedModel
Previous research illuminated many aspects of illness
progression in BD, including factors that contribute to
morbidity and psychosocial disability. This paper examines
the eﬀects of illness severity, cognitive impairment, anxiety,
genetics, and psychosocial stress on functional outcome in
BD. The interplay among these factors may be complex and
involve reciprocal pathways. Figure 1 presents 13 possible
interconnected pathways that potentially trap people with
BD in a malignant cycle that accelerates psychosocial decline.
The numbers that appear on the arrows in the ﬁgure match
those of the pathways described below.
Pathway 1. There is a strong genetic component in BD that
inﬂuences the onset, severity, and progression of the illness.
Pathway 2. T h es y m p t o m so fB Dh a v ead i r e c ti m p a c t
on psychosocial functioning. Recurrent mood disturbance,
lingering residual symptoms between episodes, hospital-
izations, comorbid substance use disorders, and psychosis
disrupt the consistency of psychosocial engagement required
for functional development.
Pathway 3. Recurrent episodes of mood disturbance result
in chronic physiological stress related to the hyperarousal of
the autonomic nervous system and HPA axis.
Pathway 4. The physiological eﬀects of stress are neurotoxic
and lead to cognitive decline over time.
Pathway 5. Cognitive impairment in general, and executive
dysfunction in particular, hampers the ability to meet psy-
chosocial demand.
Pathway 6. The diﬃculty in meeting psychosocial demand
creates disruption to social rhythm and increases environ-
mental stress.
Pathway 7. Environmental stress in general, and psychoso-
cial stress in particular, aggravates the phenotypic expression
of mood disturbance, leading to a more severe course of
illness.
Pathway 8. The consequent intensiﬁcation in symptoms and
their recurrence exacerbate the disruption to social rhythm
and environmental stress.
Pathway 9. Psychosocial stress contributes to chronic hyper-
arousal of the autonomic nervous system and HPA axis.
Pathway 10. Repeated experiences of psychosocial failure in-
tensify anxiety related to psychosocial demand.
Pathway 11. Anxiety has acute eﬀects on cognitive function-
ing during psychosocial challenges. Superimposed on cog-
nitive impairment, anxiety further compromises attentional
control and executive functions.Depression Research and Treatment 5
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Figure 1: The malignant cycle in bipolar disorder.
Pathway 12. The speciﬁc encounter between cognitive im-
pairment and challenges in a psychosocial context worsens
anxiety.
Pathway 13. The anxiety associated with functional chal-
lenges leads to avoidance of psychosocial demand and mar-
ginal psychosocial engagement.
8. Implications for Care
The model presented in Figure 1 approaches BD from
a holistic perspective. Well-embedded in diathesis-stress
notions, the model traces the roots of pathology and
psychosocial dysfunction in BD primarily to the interaction
between the person and the environment. The model places
particular importance on the psychosocial environment, as
opposed to other sources of stress that can aggravate the
illness. Central to this notion is the goodness of ﬁt between
the person and the psychosocial environment. Chronic
dissonance in this relationship may lead to a more severe
course of illness and a malignant decline in functioning.
Within any given individual, genetic predisposition toward
BD remains constant; therefore, improvement may occur as
a function of changes in the psychosocial environment. This
conclusion may deserve particular attention when failure
to thrive continues despite substantial therapeutic and phar-
macological eﬀorts to overcome the eﬀects of the illness.
In many such cases, psychosocial avoidance may lead to
disability even in the absence of acute symptoms. In other
cases, the misﬁt between the person and the psychosocial
environment may override the eﬀects of medication, so the
person remains disabled by the recurrence of symptoms.
In the current social and economic climate, goodness
of ﬁt between the person and psychosocial environment
receives far less attention than pharmacological interven-
tions. In BD, the beneﬁcial eﬀects of medications are pow-
erful for many people, but they still oﬀer limited remedy for
the illness. Psychosocial disability in BD often lingers despite
medication, possibly in part because medications typically
do not alleviate cognitive impairment [131, 132]a n dm a y ,6 Depression Research and Treatment
in fact, aggravate it [133, 134]. Although medication can
improve psychosocial functioning in BD in general by ame-
liorating aﬀective symptoms [135], pharmacological inter-
ventions alone may not have suﬃcient power to overcome
the destabilizing eﬀects of psychosocial demands that exceed
the person’s functional capacities [7].
People with BD who strive to ﬂourish against a current
of psychosocial demand that is too stressful for their genetic
level of stress tolerance may ultimately experience exhaus-
tion, intense anxiety, and decompensation [7, 136]. Hospi-
talization may help to temporarily alleviate this experience.
In this process, the chemical eﬀects of pharmacology often
reduce mood symptoms within the custodial environment
of inpatient care. However, discharging the person into the
same unworkable situation may result in recurrent decom-
pensation and a sizable increase in the number and dose of
prescribed medications over time.
Toremainstableunderthesecircumstances,manypeople
with BD may choose to disengage from the natural pursuit
of psychosocial development and seek the protective beneﬁts
of disability. Initially, this may bring some relief; however,
tradingpsychiatricsymptomsforpsychosocialdisabilitymay
become problematic over time. The stagnancy and social
marginalization that may be created by disability can be det-
rimental to a person’s identity and self-esteem [66, 137–139].
As time passes, the developmental gaps from the person’s
cohort widen, and the consequent changes to the person’s
identity and belief system diminish the probability of revers-
ing the trend from psychosocial decline to growth [140].
Aside from medication, psychosocial interventions and
support groups are also vital to improving functional out-
come in BD. Support groups and psychotherapy oﬀer a
contextinwhichpeoplecanexperienceacceptance,apprecia-
tion and meaningful interpersonal connections. Some inter-
ventions such as interpersonal and social rhythm therapy
(IPSRT) may also enhance psychosocial competence in BD
[141].
At the same time, these eﬀorts may not be powerful
enough to override a misﬁt between genetic vulnerability to
stress and psychosocial demand. If people are unable to
maintain consistent social and professional growth that is
commensurate with their potential outside therapeutic set-
tings, their lives remain limited by psychiatric illness and
functional disability.
To overcome this problem, clinicians working with BD
may need to develop expertise in helping people identify
psychosocial contexts that facilitate growth. Learning to
conduct, or at least interpret, cognitive assessments with
ecologically valid interpretations would likely be fundamen-
tal to this process [142]. Clinicians who understand the in-
terplay between a given proﬁle of cognitive deﬁcits and par-
ticular environments may be able to guide people toward
settings that increase the likelihood of psychosocial success.
Clinicians may also be able to provide persons with BD
ongoing guidance with respect to goal-related expectations,
pace of progress, and workload [143, 144].
Moving from assessment to implementing recommen-
dations regarding psychosocial adjustment for persons with
BD will require clinicians to pay particular attention to the
anxiety related to psychosocial demand. The fear of repeated
psychosocial failure can lead to the avoidance of functional
challenges and to feelings of helplessness and hopelessness.
Helping people with cognitive impairment and mood insta-
bility overcome the impediments these factors create may
require a great deal of expertise and potentially even more
highly specialized programs—for instance, an intervention
may combine elements of IPSRT with vocational counseling
tailored to BD [145], cognitive remediation [146], and other
interpersonal therapy. Traditional practices of vocational
counseling alone may not suﬃce.
The delivery of psychosocial interventions aimed at im-
proving social and occupational outcomes needs to be par-
ticularly sensitive to cognitive impairment and residual
symptoms. As previously noted, longitudinal studies show
that two key predictors of future social and occupational
functioning in BD are subsyndromal depressive symptoms
and cognitive deﬁcits, particularly in executive functioning
[25, 31, 147]. Cognitive impairment and residual depressive
symptoms in BD have also been found to correlate with
each other, independent of other outcomes [148]. Manic and
depressive residual symptoms that are present during early
remission from a mood episode also predict relapse [149],
while cognitive dysfunction impedes the eﬀectiveness of
psychosocial interventions designed to improve functioning
[145, 150] and reduces treatment adherence [151].
Given the impact of both residual symptoms and cogni-
tiveimpairment onfunctioning, andthecorrelationbetween
them, a thorough assessment of each should be included as
part of the standard of care in BD. With respect to cog-
nitive functioning, patient reports may not provide a suf-
ﬁcient indication of cognitive status, as these show weak
correlations with objective assessments [152]. To adequately
identify cognitive dysfunction in BD, assessment using a
standard neuropsychological battery may need to become
routine, as cognitive deﬁcits in BD typically do not present
when evaluated with the minimental status exam (MMSE)
[55] commonly used by clinicians.
In the future, identiﬁed cognitive deﬁcits may be
addressed to some degree with direct interventions including
compensatory [146] and restorative cognitive remediation
programs [153]b o t hm a n u a l i z e d[ 154] and computerized
[155]. Meta-analyses have found small-to-medium eﬀect
sizes for improving cognition using restorative cognitive
remediation programs in several psychiatric conditions in-
cluding schizophrenia [153] and substance use disorders
[155]. In BD, ﬁndings so far are limited to a small, uncon-
trolled study involving a compensatory cognitive skills train-
ing program [146]. This study found that traditional CBT
aimed at reducing residual depressive symptoms, combined
withsessionsteachingcompensatorycognitiveskills,resulted
in signiﬁcant improvement in occupational outcomes for
eighteen people with BD. Several clinical trials aimed at
determining the eﬃciency and occupational outcomes of
restorative cognitive remediation and pharmacologicalinter-
ventions in BD are ongoing [156, 157] and await conclusion.
Even when not directly targeted, cognitive deﬁcits in
BD may require that psychosocial interventions such as
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that accommodates cognitive disability [145, 158, 159]. Mul-
tiple ﬁndings indicate that psychoeducational interventions
aimed at relapse prevention are eﬀective and may improve
functioning in BD, highlighting the need for these inter-
ventions to be accessible to the cognitively impaired [159].
Finally, psychoeducation regarding cognitive impairment
itself may help persons with BD learn supportive techniques
andstrategiestocompensateforsuchdeﬁcitsinoccupational
settings [146].
After clients take action to re-engage in occupational
pursuits, counselors may need to help them persevere in
the face of the natural frustrations that accompany eﬀorts
to obtain psychosocial accomplishments on an alternative
schedule. Counselors may also need to assess and monitor
the person’s stress eﬀectively. Taking signiﬁcant steps toward
psychosocial development in BD is desirable but can increase
stress, and thus lead to relapse. Clinicians will likely be chal-
lenged to help clients manage the stress without abandoning
their quest for psychosocial growth or resigning themselves
to a state of disability.
Given all of these challenges, progress toward psychoso-
cial growth in BD may well be inconsistent. In many
cases, a successful outcome of counseling would be to keep
the growth from being eliminated completely in the face
of recurring symptoms. Ultimately, a positive trend in psy-
chosocial growth may be more important than measuring
any one sizable change in outcome. Mild but valued move-
ment toward growth with manageable stress may prove to
be an eﬀective mood stabilizer. Conversely, the absence of
psychosocial growth may lead to a malignant decline in fun-
ctioning.
Finally, further advances in functional outcomes for
p e r s o n sw i t hB Dw i l lp r o b a b l yr e q u i r ec h a n g e si nt h es o -
cial climate. At present, few mainstream environments
accommodatethespecialneedsofpeoplewithBD.Moreover,
stigma and discrimination against people with mental illness
in the workplace remain major obstacles for psychosocial
growth in BD [66, 68, 137, 160, 161]. Consequently, in most
settings, the intensity of functional demands and inhos-
pitable atmosphere may be too stressful to negotiate with
suﬃcient long-term consistency. In the absence of ongoing
support, the chronic mismatch between the functional limi-
tations of persons with BD and the environmental demands
they face greatly impedes their psychosocial adjustment and
development. Developing eﬀective support for psychiatric
disability in mainstream settings may, therefore, improve
clinical and functional outcomes. More broadly, mainstream
support and an inclusive shift in social climate may be
essential for curbing the downward psychosocial spiral that
so many people with BD experience after illness onset.
In conclusion, the factors that contribute to psychosocial
impairment in BD may be looped together in intricate ways,
creating an eﬀect that traps people in a course of functional
decline. Altering this downward trajectory may require both
searching for and actively creating psychosocial environ-
ments that are hospitable to the speciﬁc needs of people who
suﬀer from BD. In basic conception, psychosocial disability
is environmentally dependent and not a constant. For this
reason, in addition to medications and conventional forms
of therapy, a strategic approach that enhances the goodness
of ﬁt between persons with BD and their psychosocial en-
vironment may change their possible functional outcomes.
Most importantly, improving this ﬁt may shift the lifelong
path of persons with BD from malignant psychosocial
decline to growth.
References
[1] N. Angier, “An old idea about genius wins new scientiﬁc
support,” The New York Times, October 1993.
[2] D. Blumer, “The illness of Vincent van Gogh,” American
Journal of Psychiatry, vol. 159, no. 4, pp. 519–526, 2002.
[ 3 ]J .H .M a c C a b e ,M .P .L a m b e ,S .C n a t t i n g i u se ta l . ,“ E x c e l l e n t
school performance at age 16 and risk of adult bipolar
disorder: national cohort study,” British Journal of Psychiatry,
vol. 196, no. 2, pp. 109–115, 2010.
[4] R.DasGuptaandJ.F.Guest,“Annualcostofbipolardisorder
to UK society,” BritishJournalofPsychiatry,vol.180,pp.227–
233, 2002.
[ 5 ]J .F .G o l d b e r ga n dM .H a r r o w ,Bipolar Disorders: Clinical
Course and Outcome, American Psychiatric Press, Washing-
ton, DC, USA, 1999.
[6] A. Martinez-Aran, E. Vieta, C. Torrent et al., “Functional
outcomeinbipolardisorder:theroleofclinicalandcognitive
factors,” Bipolar Disorders, vol. 9, no. 1-2, pp. 103–113, 2007.
[7] J. Sanchez-Moreno, A. Martinez-Aran, R. Tabar´ es-Seisdedos,
C. Torrent, E. Vieta, and J. L. Ayuso-Mateos, “Functioning
and disability in bipolar disorder: an extensive review,”
PsychotherapyandPsychosomatics,vol.78,no.5,pp.285–297,
2009.
[8] T. Treuer and M. Tohen, “Predicting the course and outcome
of bipolar disorder: a review,” European Psychiatry, vol. 25,
no. 6, pp. 328–333, 2010.
[9] R. Bhattacharyya, M. K. Ghoshal, D. Sanyal, P. Guha, and
S. Chakraborty, “Issues in estimating the course of rapid-
cycling bipolar disorder,” American Journal of Psychiatry, vol.
166, no. 3, p. 370, 2009.
[10] J. F. Goldberg, J. L. Garno, and M. Harrow, “Long-term
remissionandrecoveryinbipolardisorder:areview,”Current
Psychiatry Reports, vol. 7, no. 6, pp. 456–461, 2005.
[11] E. Vieta, “Long-term treatment of bipolar depression and
other issues,” The Journal of Clinical Psychiatry, vol. 71, no.
3, article e07, 2010.
[12] J. F. Goldberg, M. Harrow, and L. S. Grossman, “Course and
outcome in bipolar aﬀective disorder: a longitudinal follow-
up study,” American Journal of Psychiatry, vol. 152, no. 3, pp.
379–384, 1995.
[13] K. E. Burdick, J. F. Goldberg, and M. Harrow, “Neurocogni-
tive dysfunction and psychosocial outcome in patients with
bipolar I disorder at 15 year follow-up,” Acta Psychiatrica
Scandinavica, vol. 122, no. 6, pp. 499–506, 2010.
[14] M.N.Pavuluri,L.S.Schenkel,S.Aryaletal.,“Neurocognitive
function in unmedicated manic and medicated euthymic
pediatric bipolar patients,” American Journal of Psychiatry,
vol. 163, no. 2, pp. 286–293, 2006.
[15] M. N. Pavuluri, A. West, S. K. Hill, K. Jindal, and J. A.
Sweeney, “Neurocognitive function in pediatric bipolar dis-
order:3-yearfollow-upshowscognitivedevelopmentlagging
behind healthy youths,” Journal of the American Academy of
Child and Adolescent Psychiatry, vol. 48, no. 3, pp. 299–307,
2009.8 Depression Research and Treatment
[16] J. Sanchez-Moreno, A. Martinez-Aran, H. F. Gadelrab et al.,
“The role and impact of contextual factors on functioning in
patients with bipolar disorder,” Disability and Rehabilitation,
vol. 32, no. 1, pp. S94–S104, 2010.
[17] A. M. Passarotti, J. A. Sweeney, and M. N. Pavuluri, “Diﬀer-
entialengagementofcognitiveandaﬀectiveneuralsystemsin
pediatric bipolar disorder and attention deﬁcit hyperactivity
disorder,” Journal of the International Neuropsychological
Society, vol. 16, no. 1, pp. 106–117, 2010.
[18] P. L. Rock, G. M. Goodwin, and C. J. Harmer, “The
common adolescent bipolar phenotype shows positive biases
in emotional processing,” Bipolar Disorders,v o l .1 2 ,n o .6 ,p p .
606–615, 2010.
[19] M. Cannon, P. Jones, C. Gilvarry et al., “Premorbid social
functioning in schizophrenia and bipolar disorder: similari-
ties and diﬀerences,” American Journal of Psychiatry, vol. 154,
no. 11, pp. 1544–1550, 1997.
[20] A. Reichenberg, M. Weiser, J. Rabinowitz et al., “A
population-based cohort study of premorbid intellectual,
language, and behavioral functioning in patients with
schizophrenia, schizoaﬀective disorder, and nonpsychotic
bipolardisorder,”AmericanJournalofPsychiatry,vol.159,no.
12, pp. 2027–2035, 2002.
[21] M. Rietschel, A. Georgi, C. Schmael et al., “Premorbid
adjustment: a phenotype highlighting a distinction rather
thananoverlapbetweenschizophreniaandbipolardisorder,”
Schizophrenia Research, vol. 110, no. 1–3, pp. 33–39, 2009.
[22] S. Uzelac, J. Jaeger, S. Berns, and C. Gonzales, “Premorbid
adjustmentinbipolardisorder:comparisonwithschizophre-
nia,” Journal of Nervous and Mental Disease, vol. 194, no. 9,
pp. 654–658, 2006.
[23] L. L. Judd, P. J. Schettler, D. A. Solomon et al., “Psychosocial
disability and work role function compared across the long-
term course of bipolar I, bipolar II and unipolar major
depressive disorders,” Journal of Aﬀective Disorders, vol. 108,
no. 1-2, pp. 49–58, 2008.
[24] L. L. Judd, H. S. Akiskal, P. J. Schettler et al., “Psychosocial
disability in the course of bipolar I and II disorders: a
prospective, comparative, longitudinal study,” Archives of
General Psychiatry, vol. 62, no. 12, pp. 1322–1330, 2005.
[25] C. M. Bonn´ ın, A. Mart´ ınez-Ar´ an, C. Torrent et al., “Clinical
and neurocognitive predictors of functional outcome in
bipolar euthymic patients: a long-term, follow-up study,”
Journal of Aﬀective Disorders, vol. 121, no. 1-2, pp. 156–160,
2010.
[26] B. Arts, N. Jabben, L. Krabbendam, and J. Van Os, “Meta-
analyses of cognitive functioning in euthymic bipolar pa-
tients and their ﬁrst-degree relatives,” Psychological Medicine,
vol. 38, no. 6, pp. 771–785, 2008.
[27] L. J. Robinson, J. M. Thompson, P. Gallagher et al., “A
meta-analysis of cognitive deﬁcits in euthymic patients with
bipolar disorder,” Journal of Aﬀective Disorders, vol. 93, no.
1–3, pp. 105–115, 2006.
[28] I. J. Torres, V. G. Boudreau, and L. N. Yatham, “Neuropsy-
chological functioning in euthymic bipolar disorder: a meta-
analysis,” Acta Psychiatrica Scandinavica, vol. 116, no. 434,
pp. 17–26, 2007.
[29] G. S. Malhi, B. Ivanovski, D. Hadzi-Pavlovic, P. B. Mitchell,
E. Vieta, and P. Sachdev, “Neuropsychological deﬁcits and
functional impairment in bipolar depression, hypomania
andeuthymia,”BipolarDisorders,vol.9,no.1-2,pp.114–125,
2007.
[30] A. Montoya, M. Tohen, E. Vieta et al., “Functioning and
symptomatic outcomes in patients with bipolar i disorder
in syndromal remission: a 1-year, prospective, observational
cohort study,” Journal of Aﬀective Disorders, vol. 127, no. 1–3,
pp. 50–57, 2010.
[ 3 1 ]M .M u r ,M .J .P o r t e l l a ,A .M a r t i n e z - A r a n ,J .P i f a r r e ,a n dE .
Vieta, “Inﬂuence of clinical and neuropsychological variables
on the psychosocial and occupational outcome of remitted
bipolar patients,” Psychopathology, vol. 42, no. 3, pp. 148–
156, 2009.
[32] A. P. Wingo, P. D. Harvey, and R. J. Baldessarini, “Neurocog-
nitive impairment in bipolar disorder patients: functional
implications,” Bipolar Disorders, vol. 11, no. 2, pp. 113–125,
2009.
[33] F. Dickerson, A. Origoni, C. Stallings, S. Khushalani, D.
Dickinson, and D. Medoﬀ, “Occupational status and social
adjustment six months after hospitalization early in the
course of bipolar disorder: a prospective study,” Bipolar
Disorders, vol. 12, no. 1, pp. 10–20, 2010.
[34] J. Jaeger, S. Berns, S. Loftus, C. Gonzalez, and P. Czobor,
“Neurocognitive test performance predicts functional recov-
ery from acute exacerbation leading to hospitalization in
bipolar disorder,” Bipolar Disorders, vol. 9, no. 1-2, pp. 93–
102, 2007.
[35] D .J .M artino ,E.M ar engo ,A.I goaetal.,“N eur oc ogniti v eand
symptomatic predictors of functional outcome in bipolar
disorders: a prospective 1 year follow-up study,” Journal of
Aﬀective Disorders, vol. 116, no. 1-2, pp. 37–42, 2009.
[36] M. Mur, M. J. Portella, A. Mart´ ınez-Ar´ an, J. Pifarr´ e, and
E. Vieta, “Long-term stability of cognitive impairment in
bipolar disorder: a 2-year follow-up study of lithium-treated
euthymic bipolar patients,” The Journal of Clinical Psychiatry,
vol. 69, no. 5, pp. 712–719, 2008.
[37] R. Tabar´ es-Seisdedos, V. Balanz´ a-Mart´ ınez, J. S´ anchez-
Moreno et al., “Neurocognitive and clinical predictors of
functional outcome in patients with schizophrenia and
bipolar I disorder at one-year follow-up,” Journal of Aﬀective
Disorders, vol. 109, no. 3, pp. 286–299, 2008.
[ 3 8 ]H .H .E l s h a h a w i ,H .E s s a w i ,M .A .R a b i e ,M .M a n s o u r ,Z .
A. Beshry, and A. N. Mansour, “Cognitive functions among
euthymic bipolar I patients after a single manic episode
versus recurrent episodes,” J o u r n a lo fA ﬀective Disorders, vol.
130, no. 1-2, pp. 180–191, 2010.
[39] C. L´ opez-Jaramillo, J. Lopera-V´ asquez, A. Gallo et al.,
“Eﬀects of recurrence on the cognitive performance of
patients with bipolar I disorder: implications for relapse
prevention and treatment adherence,” Bipolar Disorders, vol.
12, no. 5, pp. 557–567, 2010.
[40] D. B. Yates, S. Dittmann, F. Kapczinski, and C. M. Tren-
tini, “Cognitive abilities and clinical variables in bipolar I
depressed and euthymic patients and controls,” Journal of
Psychiatric Research, vol. 45, no. 4, pp. 495–504, 2010.
[41] A. G. Gildengers, B. H. Mulsant, A. Begley et al., “The
longitudinal course of cognition in older adults with bipolar
disorder,” Bipolar Disorders, vol. 11, no. 7, pp. 744–752, 2009.
[42] J. R. Sadek, D. A. White, K. I. Taylor et al., “Retro-
grade amnesia in dementia: comparison of HIV-associated
dementia, Alzheimer’s disease, and Huntington’s disease,”
Neuropsychology, vol. 18, no. 4, pp. 692–699, 2004.
[43] M. Mur, M. J. Portella, A. Mart´ ınez-Ar´ an, J. Pifarr´ e, and
E. Vieta, “Persistent neuropsychological deﬁcit in euthymic
bipolar patients: executive function as a core deﬁcit,” The
Journal of Clinical Psychiatry, vol. 68, no. 7, pp. 1078–1086,
2007.
[44] L. Clark, A. Sarna, and G. M. Goodwin, “Impairment of
executive function but not memory in ﬁrst-degree relativesDepression Research and Treatment 9
of patients with bipolar I disorder and in euthymic patients
with unipolar depression,” American Journal of Psychiatry,
vol. 162, no. 10, pp. 1980–1982, 2005.
[ 4 5 ] J .M .T h o m p s o n ,J .M .G r a y ,J .R .C r a w f o r d ,J .H .H u g h e s ,A .
H. Young, and I. N. Ferrier, “Diﬀerential deﬁcit in executive
control in euthymic bipolar disorder,” Journal of Abnormal
Psychology, vol. 118, no. 1, pp. 146–160, 2009.
[46] A. G. Gildengers, M. A. Butters, D. Chisholm et al., “Cog-
nitive functioning and instrumental activities of daily living
in late-life bipolar disorder,” American Journal of Geriatric
Psychiatry, vol. 15, no. 2, pp. 174–179, 2007.
[47] S. Bell-McGinty, K. Podell, M. Franzen, A. D. Baird, and
M. J. Williams, “Standard measures of executive function
in predicting instrumental activities of daily living in older
adults,” International Journal of Geriatric Psychiatry, vol. 17,
no. 9, pp. 828–834, 2002.
[48] M. Mitchell and L. S. Miller, “Prediction of functional status
in older adults: the ecological validity of four Delis-Kaplan
Executive Function System tests,” Journal of Clinical and
Experimental Neuropsychology, vol. 30, no. 6, pp. 683–690,
2008.
[49] D. R. Royall, R. Palmer, L. K. Chiodo, and M. J. Polk,
“Decliningexecutivecontrolinnormalagingpredictschange
infunctionalstatus:theFreedomHouseStudy,”Journalofthe
American Geriatrics Society, vol. 52, no. 3, pp. 346–352, 2004.
[50] J. Biederman, C. R. Petty, J. Wozniak et al., “Impact of ex-
ecutive function deﬁcits in youth with bipolar I disorder: a
controlled study,” Psychiatry Research, vol. 186, no. 1, pp. 58–
64, 2010.
[51] L.Altshuler,J.Tekell,K.Biswasetal.,“Executivefunctionand
employment status among veterans with bipolar disorder,”
Psychiatric Services, vol. 58, no. 11, pp. 1441–1447, 2007.
[52] C. F. Yen, C. P. Cheng, C. F. Huang et al., “Relationship
between psychosocial adjustment and executive function
in patients with bipolar disorder and schizophrenia in
remission: the mediating and moderating eﬀects of insight,”
Bipolar Disorders, vol. 11, no. 2, pp. 190–197, 2009.
[53] S. Brissos, V. V. Dias, A. I. Carita, and A. Martinez-Ar´ an,
“Quality of life in bipolar type I disorder and schizophrenia
in remission: clinical and neurocognitive correlates,” Psychi-
atry Research, vol. 160, no. 1, pp. 55–62, 2008.
[54] S. Brissos, V. V. Dias, and F. Kapczinski, “Cognitive per-
formance and quality of life in bipolar disorder,” Canadian
Journal of Psychiatry, vol. 53, no. 8, pp. 517–524, 2008.
[55] J. F. Goldberg and K. E. Burdick, Cognitive Dysfunction in
Bipolar Disorder, American Psychiatric Publishing, Arling-
ton, Va, USA, 2008.
[56] A. M. Gilbert, T. M. Olino, P. Houck, A. Fagiolini, D.
J. Kupfer, and E. Frank, “Self-reported cognitive problems
predict employment trajectory in patients with bipolar I
disorder,” Journal of Aﬀective Disorders, vol. 124, no. 3, pp.
324–328, 2010.
[ 5 7 ]P .E .K e c k ,S .L .M c E l r o y ,S .M .S t r a k o w s k ie ta l . ,“ 1 2 -
month outcome of patients with bipolar disorder following
hospitalization for a manic or mixed episode,” American
Journal of Psychiatry, vol. 155, no. 5, pp. 646–652, 1998.
[58] J. C. Hays, K. R. R. Krishnan, L. K. George, and D. G. Blazer,
“Age of ﬁrst onset of bipolar disorder: demographic, family
history, and psychosocial correlates,” Depression and Anxiety,
vol. 7, no. 2, pp. 76–82, 1998.
[59] L. L. Judd, P. J. Schettler, H. S. Akiskal et al., “Residual
s y m p t o mr e c o v e r yf r o mm a j o ra ﬀective episodes in bipolar
disorders and rapid episode relapse/recurrence,” Archives of
General Psychiatry, vol. 65, no. 4, pp. 386–394, 2008.
[60] L. B. Marangell, E. B. Dennehy, S. Miyahara et al., “The
functional impact of subsyndromal depressive symptoms in
bipolar disorder: data from STEP-BD,” Journal of Aﬀective
Disorders, vol. 114, no. 1–3, pp. 58–67, 2009.
[61] L. L. Hua, T. E. Wilens, M. Martelon, P. Wong, J. Wozniak,
and J. Biederman, “Psychosocial functioning, familiality, and
psychiatric comorbidity in bipolar youth with and without
psychotic features,” The Journal of Clinical Psychiatry, vol. 72,
no. 3, pp. 397–405, 2011.
[62] F. Jaworski, C. Dubertret, J. Ad` es, and P. Gorwood, “Presence
of co-morbid substance use disorder in bipolar patients
worsens their social functioning to the level observed in
patients with schizophrenia,” Psychiatry Research, vol. 185,
no. 1-2, pp. 129–134, 2011.
[63] T. V. Lagerberg, O. A. Andreassen, P. A. Ringen et al.,
“Excessivesubstanceuseinbipolardisorderisassociatedwith
impaired functioning rather than clinical characteristics, a
descriptive study,” BMC Psychiatry, vol. 10, article 9, 2010.
[ 6 4 ]R .H .P e r l i s ,E .B .D e n n e h y ,D .J .M i k l o w i t ze ta l . ,“ R e t r o -
spective age at onset of bipolar disorder and outcome during
two-yearfollow-up:resultsfromtheSTEP-BDstudy,”Bipolar
Disorders, vol. 11, no. 4, pp. 391–400, 2009.
[65] R. M. Post, G. S. Leverich, R. W. Kupka et al., “Early-onset
bipolar disorder and treatment delay are risk factors for poor
outcome in adulthood,” The Journal of Clinical Psychiatry,
vol. 71, no. 7, pp. 864–872, 2010.
[66] E. Michalak, J. D. Livingston, R. Hole et al., “‘It’s something
that I manage but it is not who I am’: reﬂections on
internalized stigma in individuals with bipolar disorder,”
Chronic Illness, vol. 7, no. 3, pp. 209–224, 2011.
[67] P. Corrigan, “How stigma interferes with mental health care,”
American Psychologist, vol. 59, no. 7, pp. 614–625, 2004.
[68] E. E. Michalak, L. N. Yatham, S. Kolesar, and R. W. Lam,
“Bipolar disorder and quality of life: a patient-centered
perspective,” Quality of Life Research, vol. 15, no. 1, pp. 25–
37, 2006.
[69] D. A. Perlick, R. A. Rosenheck, J. F. Clarkin et al., “Adverse
eﬀects of perceived stigma on social adaptation of persons
diagnosed with bipolar aﬀective disorder,” Psychiatric Ser-
vices, vol. 52, no. 12, pp. 1627–1632, 2001.
[70] T. L. Scheid, “Stigma as a barrier to employment: mental dis-
abilityandtheAmericanswithDisabilitiesAct,”International
Journal of Law and Psychiatry, vol. 28, no. 6, pp. 670–690,
2005.
[71] G. H. V´ azquez, F. Kapczinski, P. V. Magalhaes et al., “Stigma
and functioning in patients with bipolar disorder,” Journal of
Aﬀective Disorders, vol. 130, no. 1-2, pp. 323–327, 2010.
[72] D. C. Glahn, C. E. Bearden, C. L. Bowden, and J. C. Soares,
“Reduced educational attainment in bipolar disorder,” Jour-
nal of Aﬀective Disorders, vol. 92, no. 2-3, pp. 309–312, 2006.
[73] N.HuxleyandR.J.Baldessarini,“Disabilityanditstreatment
inbipolardisorderpatients,”BipolarDisorders,vol.9,no.1-2,
pp. 183–196, 2007.
[74] A. P. Wingo, R. J. Baldessarini, M. T. Compton, and P. D.
Harvey, “Correlates of recovery of social functioning in types
I and II bipolar disorder patients,” Psychiatry Research, vol.
177, no. 1-2, pp. 131–134, 2010.
[75] L. N. Yatham, M. Kauer-SanT’Anna, D. J. Bond, R. W.
Lam, and I. Torres, “Course and outcome after the ﬁrst
manic episode in patients with bipolar disorder: prospective
12-month data from the systematic treatment optimization
program for early mania project,” Canadian Journal of
Psychiatry, vol. 54, no. 2, pp. 105–112, 2009.10 Depression Research and Treatment
[76] G. M. Goodwin, A. Martinez-Aran, D. C. Glahn, and E.
Vieta, “Cognitive impairment in bipolar disorder: neurode-
velopment or neurodegeneration? An ECNP expert meeting
report,” European Neuropsychopharmacology, vol. 18, no. 11,
pp. 787–793, 2008.
[77] A. Mart´ ınez-Ar´ an, E. Vieta, F. Colom et al., “Cognitive
impairment in euthymic bipolar patients: implications for
clinical and functional outcome,” Bipolar Disorders, vol. 6,
no. 3, pp. 224–232, 2004.
[78] A. Mart´ ınez-Ar´ an, E. Vieta, M. Reinares et al., “Cogni-
tive function across manic or hypomanic, depressed, and
euthymic states in bipolar disorder,” American Journal of
Psychiatry, vol. 161, no. 2, pp. 262–270, 2004.
[79] B. Levy, M. R. Stephansky, K. C. Dobie, B. A. Monzani, A.
M. Medina, and R. D. Weiss, “The duration of inpatient
admission predicts cognitive functioning at discharge in
patients with bipolar disorder,” Comprehensive Psychiatry,
vol. 50, no. 4, pp. 322–326, 2009.
[80] F. Kapczinski, E. Vieta, A. C. Andreazza et al., “Allostatic load
in bipolar disorder: implications for pathophysiology and
treatment,” Neuroscience and Biobehavioral Reviews, vol. 32,
no. 4, pp. 675–692, 2008.
[81] B. S. McEwen and J. C. Wingﬁeld, “The concept of allostasis
inbiologyandbiomedicine,”HormonesandBehavior,vol.43,
no. 1, pp. 2–15, 2003.
[82] I. C. Chien, K. C. Chang, C. H. Lin, Y. J. Chou, and P. Chou,
“Prevalence of diabetes in patients with bipolar disorder in
Taiwan: a population-based national health insurance study,”
General Hospital Psychiatry, vol. 32, no. 6, pp. 577–582, 2010.
[83] A. Fagiolini, K. N. R. Chengappa, I. Soreca, and J. Chang,
“Bipolar disorder and the metabolic syndrome: causal
factors, psychiatric outcomes and economic burden,” CNS
Drugs, vol. 22, no. 8, pp. 655–669, 2008.
[84] J. G. Fiedorowicz, N. M. Palagummi, V. L. Forman-Hoﬀman,
D. D. Miller, and W. G. Haynes, “Elevated prevalence of
obesity, metabolic syndrome, and cardiovascular risk factors
in bipolar disorder,” Annals of Clinical Psychiatry, vol. 20, no.
3, pp. 131–137, 2008.
[ 8 5 ] A .V .S t e c k e r t ,S .S .V a l v a s s o r i ,M .M o r e t t i ,F .D a l - P i z z o l ,a n d
J. Quevedo, “Role of oxidative stress in the pathophysiology
of bipolar disorder,” Neurochemical Research, vol. 35, no. 9,
pp. 1295–1301, 2010.
[86] M. Berk, F. Kapczinski, A. C. Andreazza et al., “Pathways
underlying neuroprogression in bipolar disorder: focus on
inﬂammation, oxidative stress and neurotrophic factors,”
Neuroscience and Biobehavioral Reviews,v o l .3 5 ,n o .3 ,p p .
804–817, 2011.
[87] D. Arnone, J. Cavanagh, D. Gerber, S. M. Lawrie, K. P.
Ebmeier, and A. M. McIntosh, “Magnetic resonance imaging
studiesinbipolardisorderandschizophrenia:meta-analysis,”
British Journal of Psychiatry, vol. 195, no. 3, pp. 194–201,
2009.
[88] S.M.Strakowski,C.M.Adler,S.K.Holland,N.P.Mills,M.P.
DelBello,andJ.C.Eliassen,“AbnormalfMRIbrainactivation
in euthymic bipolar disorder patients during a counting
stroop interference task,” American Journal of Psychiatry, vol.
162, no. 9, pp. 1697–1705, 2005.
[89] I. Forcada, E. Papachristou, M. Mur et al., “The impact of
general intellectual ability and white matter volume on the
functional outcome of patients with Bipolar Disorder and
their relatives,” Journal of Aﬀective Disorders, vol. 130, no. 3,
pp. 413–430, 2010.
[90] N. M. Simon, M. W. Otto, S. R. Wisniewski et al., “Anxiety
disorder comorbidity in bipolar disorder patients: data
from the ﬁrst 500 participants in the Systematic Treatment
Enhancement Program for Bipolar Disorder (STEP-BD),”
American Journal of Psychiatry, vol. 161, no. 12, pp. 2222–
2229, 2004.
[ 9 1 ]M .P .F r e e m a n ,S .A .F r e e m a n ,a n dS .L .M c E l r o y ,“ T h e
comorbidity of bipolar and anxiety disorders: prevalence,
psychobiology, and treatment issues,” Journal of Aﬀective
Disorders, vol. 68, no. 1, pp. 1–23, 2002.
[92] R. S. El-Mallakh and M. Holliﬁeld, “Comorbid anxiety in
bipolar disorder alters treatment and prognosis,” Psychiatric
Quarterly, vol. 79, no. 2, pp. 139–150, 2008.
[93] J. M. Azorin, A. Kaladjian, M. Adida et al., “Psychopatho-
logical correlates of lifetime anxiety comorbidity in bipolar
i patients: ﬁndings from a French national cohort,” Psy-
chopathology, vol. 42, no. 6, pp. 380–386, 2009.
[94] C. Henry, D. V. Den Bulke, F. Bellivier, B. Etain, F. Rouillon,
and M. Leboyer, “Anxiety disorders in 318 bipolar patients:
prevalence and impact on illness severity and response to
mood stabilizer,” The Journal of Clinical Psychiatry, vol. 64,
no. 3, pp. 331–335, 2003.
[95] K. R. Boylan, P. J. Bieling, M. Marriott, H. Begin, L. T.
Young, and G. M. MacQueen, “Impact of comorbid anxiety
disorders on outcome in a cohort of patients with bipolar
disorder,” The Journal of Clinical Psychiatry,v o l .6 5 ,n o .8 ,p p .
1106–1113, 2004.
[96] M. S. Bauer, L. Altshuler, D. R. Evans, T. Beresford, W. O.
Williford, and R. Hauger, “Prevalence and distinct correlates
of anxiety, substance, and combined comorbidity in a multi-
site public sector sample with bipolar disorder,” Journal of
Aﬀective Disorders, vol. 85, no. 3, pp. 301–315, 2005.
[97] B. A. Gaudiano and I. W. Miller, “Anxiety disorder comobid-
ity in Bipolar I Disorder: relationship to depression severity
and treatment outcome,” Depression and Anxiety, vol. 21, no.
2, pp. 71–77, 2005.
[98] C. F. Baldassano, “Illness course, comorbidity, gender, and
suicidality in patients with bipolar disorder,” The Journal of
Clinical Psychiatry, vol. 67, supplement 11, pp. 8–11, 2006.
[99] M. Kauer-Sant’Anna, B. N. Frey, A. C. Andreazza et al.,
“Anxiety comorbidity and quality of life in bipolar disorder
patients,” Canadian Journal of Psychiatry, vol. 52, no. 3, pp.
175–181, 2007.
[100] S. Tse and M. Yeats, “What helps people with bipolar
aﬀective disordersucceed inemployment: agroundedtheory
approach,” Work, vol. 19, no. 1, pp. 47–62, 2002.
[101] F. T. Silva and J. R. Leite, “Physiological modiﬁcations and
increase in state anxiety in volunteers submitted to the
Stroop Color-Word Interference Test: a preliminary study,”
Physiology and Behavior, vol. 70, no. 1-2, pp. 113–118, 2000.
[102] A. C. Miu, R. M. Heilman, and D. Houser, “Anxiety im-
pairs decision-making: psychophysiological evidence from
an Iowa Gambling Task,” Biological Psychology, vol. 77, no.
3, pp. 353–358, 2008.
[103] B. K. Lee, T. A. Glass, M. J. McAtee et al., “Associations
of salivary cortisol with cognitive function in the Baltimore
memory study,” Archives of General Psychiatry,v o l .6 4 ,n o .7 ,
pp. 810–818, 2007.
[104] C. Daban, E. Vieta, P. Mackin, and A. H. Young, “Hypo-
thalamic-pituitary-adrenalaxisandbipolardisorder,”Psychi-
atric Clinics of North America, vol. 28, no. 2, pp. 469–480,
2005.
[105] J. Schmider, C. H. Lammers, U. Gotthardt, M. Dettling, F.
Holsboer, and I. J. E. Heuser, “Combined dexamethasone/
corticotropin-releasing hormone test in acute and remittedDepression Research and Treatment 11
manic patients, in acute depression, and in normal controls:
I,” Biological Psychiatry, vol. 38, no. 12, pp. 797–802, 1995.
[106] J. K. Rybakowski and K. Twardowska, “The
dexamethasone/corticotropin-releasing hormone test in
depression in bipolar and unipolar aﬀective illness,” Journal
of Psychiatric Research, vol. 33, no. 5, pp. 363–370, 1999.
[107] N. Kobayashi, A. Yoshino, Y. Takahashi, and S. Nomura,
“Autonomic arousal in cognitive conﬂict resolution,” Auto-
nomic Neuroscience, vol. 132, no. 1-2, pp. 70–75, 2007.
[108] E. A. Fertuck, S. Marsano-Jozefowicz, B. Stanley et al.,
“The impact of borderline personality disorder and anxiety
on neuropsychological performance in major depression,”
Journal of Personality Disorders, vol. 20, no. 1, pp. 55–70,
2006.
[109] D. Fishbein, C. Hyde, D. Eldreth et al., “Cognitive perfor-
mance and autonomic reactivity in abstinent drug abusers
and nonusers,” Experimental and Clinical Psychopharmacol-
ogy, vol. 13, no. 1, pp. 25–40, 2005.
[110] J. K. Lee, S. M. Orsillo, L. Roemer, and L. B. Allen, “Distress
and avoidance in generalized anxiety disorder: exploring the
relationships with intolerance of uncertainty and worry,”
Cognitive Behaviour Therapy, vol. 39, no. 2, pp. 126–136,
2010.
[111] P. D. Harvey, A. P. Wingo, K. E. Burdick, and R. J.
Baldessarini, “Cognition and disability in bipolar disorder:
lessons from schizophrenia research,” Bipolar Disorders, vol.
12, no. 4, pp. 364–375, 2010.
[112] F. R. Leifker, C. R. Bowie, and P. D. Harvey, “Determinants
of everyday outcomes in schizophrenia: the inﬂuences of
cognitive impairment, functional capacity, and symptoms,”
Schizophrenia Research, vol. 115, no. 1, pp. 82–87, 2009.
[113] C. Simonsen, K. Sundet, A. Vaskinn et al., “Neurocognitive
dysfunctioninbipolarandschizophreniaspectrumdisorders
depends on history of psychosis rather than diagnostic
group,”SchizophreniaBulletin,vol.37,no.1,pp.73–83,2011.
[114] R. E. Bender and L. B. Alloy, “Life stress and kindling in
bipolar disorder: review of the evidence and integration
with emerging biopsychosocial theories,” Clinical Psychology
Review, vol. 31, no. 3, pp. 383–398, 2011.
[115] K. A. Dienes, C. Hammen, R. M. Henry, A. N. Cohen, and S.
E. Daley, “The stress sensitization hypothesis: understanding
the course of bipolar disorder,” Journal of Aﬀective Disorders,
vol. 95, no. 1–3, pp. 43–49, 2006.
[116] R. T. Liu, “Early life stressors and genetic inﬂuences on
the development of bipolar disorder: the roles of childhood
abuse and brain-derived neurotrophic factor,” Child Abuse
and Neglect, vol. 34, no. 7, pp. 516–522, 2010.
[117] G. M. Hosang, R. Uher, R. Keers et al., “Stressful life events
and the brain-derived neurotrophic factor gene in bipolar
disorder,” Journal of Aﬀective Disorders, vol. 125, no. 1–3, pp.
345–349, 2010.
[118] R. E. Bender, L. B. Alloy, L. G. Sylvia, S. Uroˇ sevic, and L. Y.
Abramson, “Generation of life events in bipolar spectrum
disorders: a re-examination and extension of the stress
generation theory,” Journal of Clinical Psychology, vol. 66, no.
9, pp. 907–926, 2010.
[119] R.M.Post,“Transductionofpsychosocialstressintotheneu-
robiologyofrecurrentaﬀectivedisorder,”AmericanJournalof
Psychiatry, vol. 149, no. 8, pp. 999–1010, 1992.
[120] S. Uroˇ sevi´ c, L. Y. Abramson, E. Harmon-Jones, and L. B.
Alloy, “Dysregulation of the behavioral approach system
(BAS) in bipolar spectrum disorders: review of theory and
evidence,” Clinical Psychology Review, vol. 28, no. 7, pp.
1188–1205, 2008.
[121] S. Malkoﬀ-Schwartz, E. Frank, B. P. Anderson et al., “Social
rhythm disruption and stressful life events in the onset of
bipolar and unipolar episodes,” Psychological Medicine, vol.
30, no. 5, pp. 1005–1016, 2000.
[122] M. H. J. Hillegers, H. Burger, M. Wals et al., “Impact of
stressful life events, familial loading and their interaction on
the onset of mood disorders: study in a high-risk cohort of
adolescent oﬀspring of parents with bipolar disorder,” British
Journal of Psychiatry, vol. 185, pp. 97–101, 2004.
[123] A. N. Cohen, C. Hammen, R. M. Henry, and S. E. Daley,
“Eﬀects of stress and social support on recurrence in bipolar
disorder,” Journal of Aﬀective Disorders, vol. 82, no. 1, pp.
143–147, 2004.
[124] L. Yan-Meier, N. K. Eberhart, C. L. Hammen, M. Gitlin,
K. Sokolski, and L. Altshuler, “Stressful life events predict
delayed functional recovery following treatment for mania in
bipolar disorder,” Psychiatry Research, vol. 186, no. 2-3, pp.
267–271, 2010.
[125] G. M. Hosang, A. Korszun, L. Jones et al., “Adverse life event
reporting and worst illness episodes in unipolar and bipolar
aﬀective disorders: measuring environmental risk for genetic
research,” Psychological Medicine, vol. 40, no. 11, pp. 1829–
1837, 2010.
[126] L. Johnson, O. Lundstr¨ om, A. ˚ Aberg-Wistedt, and A. A.
Math´ e, “Social support in bipolar disorder: its relevance to
remission and relapse,” Bipolar Disorders,v o l .5 ,n o .2 ,p p .
129–137, 2003.
[127] S. L. Johnson, A. K. Cueller, C. Ruggero et al., “Life events
as predictors of mania and depression in bipolar I disorder,”
Journal of Abnormal Psychology, vol. 117, no. 2, pp. 268–277,
2008.
[128] G. H. C. Shen, L. B. Alloy, L. Y. Abramson, and L. G. Sylvia,
“Social rhythm regularity and the onset of aﬀective episodes
in bipolar spectrum individuals,” Bipolar Disorders, vol. 10,
no. 4, pp. 520–529, 2008.
[129] S. A. Hlastala and J. A. Varley, “Stress, social rhythms, and
behavioral activation: psychosocial factors and the bipolar
illness course,” Current Psychosis and Therapeutics Reports,
vol. 2, no. 4, pp. 160–166, 2004.
[130] N. Horesh and I. Iancu, “A comparison of life events in
patients with unipolar disorder or bipolar disorder and
controls,” Comprehensive Psychiatry, vol. 51, no. 2, pp. 157–
164, 2010.
[131] M. K. Holmes, K. Erickson, D. A. Luckenbaugh et al.,
“A comparison of cognitive functioning in medicated and
unmedicated subjects with bipolar depression,” Bipolar Dis-
orders, vol. 10, no. 7, pp. 806–815, 2008.
[132] U.Goswami,A.Sharma,A.Varmaetal.,“Theneurocognitive
performance of drug-free and medicated euthymic bipolar
patients do not diﬀer,” Acta Psychiatrica Scandinavica, vol.
120, no. 6, pp. 456–463, 2009.
[133] J. F. Goldberg and K. N. R. Chengappa, “Identifying and
treating cognitive impairment in bipolar disorder,” Bipolar
Disorders, vol. 11, no. 2, pp. 123–137, 2009.
[134] C. Seale, R. Chaplin, P. Lelliott, and A. Quirk, “Antipsychotic
medication, sedation and mental clouding: an observa-
tional study of psychiatric consultations,” Social Science and
Medicine, vol. 65, no. 4, pp. 698–711, 2007.
[135] V.Balanz´ a-Mart´ ınez,G.Selva,A.Mart´ ınez-Ar´ anetal.,“Neu-
rocognition in bipolar disorders-A closer look at comorbidi-
tiesandmedications,”EuropeanJournalofPharmacology,vol.
626, no. 1, pp. 87–96, 2010.
[136] B.B.Dean,D.Gerner,andR.H.Gerner,“Asystematicreview
evaluating health-related quality of life, work impairment,12 Depression Research and Treatment
and health-care costs and utilization in bipolar disorder,”
CurrentMedicalResearchandOpinion,vol.20,no.2,pp.139–
154, 2004.
[137] M. L. Baldwin and S. C. Marcus, “Stigma, discrimination,
and employment outcomes among persons with mental
health disabilities,” in Work Accommodation and Retention in
Mental Health,I .Z .S c h u l t za n dE .S .R o g e r s ,E d s . ,p p .5 3 – 6 9 ,
Springer, New York, NY, USA, 2011.
[138] K. E. Laxman, K. S. Lovibond, and M. K. Hassan, “Impact of
bipolar disorder in employed populations,” American Journal
of Managed Care, vol. 14, no. 11, pp. 757–764, 2008.
[139] M. Garaigordobil and J. I. P´ erez, “Self-concept, self-esteem
and psychopathological symptoms in persons with intellec-
tual disability,” Spanish Journal of Psychology, vol. 10, no. 1,
pp. 141–150, 2007.
[140] K. Marcussen, C. Ritter, and M. R. Munetz, “The eﬀect of
services and stigma on quality of life for persons with serious
mental illnesses,” Psychiatric Services, vol. 61, no. 5, pp. 489–
494, 2010.
[141] S. A. Hlastala, J. S. Kotler, J. M. McClellan, and E. A.
McCauley, “Interpersonal and social rhythm therapy for
adolescents with bipolar disorder: treatment development
and results from an open trial,” Depression and Anxiety, vol.
27, no. 5, pp. 457–464, 2010.
[142] R. O’Shea, R. Poz, A. Michael, G. E. Berrios, J. J. Evans,
and J. S. Rubinsztein, “Ecologically valid cognitive tests and
everyday functioning in euthymic bipolar disorder patients,”
Journal of Aﬀective Disorders, vol. 125, no. 1–3, pp. 336–340,
2010.
[143] S. Tse, “Practice guidelines: therapeutic interventions aimed
at assisting people with bipolar aﬀective disorder achieve
their vocational goals,” Work, vol. 19, no. 2, pp. 167–179,
2002.
[144] R. D. de Andr´ es, N. Aillon, M. C. Bardiot et al., “Impact of
the life goals group therapy program for bipolar patients: an
open study,” Journal of Aﬀective Disorders, vol. 93, no. 1–3,
pp. 253–257, 2006.
[145] A. Mart´ ınez-Ar´ a n ,C .T o r r e n t ,B .S o l ´ e et al., “Functional
remediation for bipolar disorder,” Clinical Practice and
Epidemiology in Mental Health, vol. 7, article 112, 2011.
[146] T. Deckersbach, A. A. Nierenberg, R. Kessler et al., “Cog-
nitive rehabilitation for bipolar disorder: an open trial for
employed patients with residual depressive symptoms,” CNS
Neuroscience and Therapeutics, vol. 16, no. 5, pp. 298–307,
2010.
[147] D. J. Martino, A. Igoa, E. Marengo, M. Sc´ apola, and S. A.
Strejilevich, “Neurocognitive impairments and their rela-
tionship with psychosocial functioning in euthymic bipolar
II disorder,” Journal of Nervous and Mental Disease, vol. 199,
no. 7, pp. 459–464, 2011.
[148] S. Frangou, S. Donaldson, M. Hadjulis, S. Landau, and
L. H. Goldstein, “The Maudsley Bipolar Disorder Project:
executive dysfunction in bipolar disorder I and its clinical
correlates,” Biological Psychiatry, vol. 58, no. 11, pp. 859–864,
2005.
[149] R. H. Perlis, M. J. Ostacher, J. K. Patel et al., “Predictors of
recurrence in bipolar disorder: primary outcomes from the
Systematic Treatment Enhancement Program for Bipolar
Disorder (STEP-BD),” American Journal of Psychiatry, vol.
163, no. 2, pp. 217–224, 2006.
[150] K. Grohman, W. Fals-Stewart, and K. Donnelly, “Improving
treatment response of cognitively impaired veterans with
neuropsychological rehabilitation,” Brain and Cognition, vol.
60, no. 2, pp. 203–204, 2006.
[151] A. Martinez-Aran, J. Scott, F. Colom et al., “Treatment
nonadherence and neurocognitive impairment in bipolar
disorder,” The Journal of Clinical Psychiatry,v o l .7 0 ,n o .7 ,p p .
1017–1023, 2009.
[152] A. Mart´ ınez-Ar´ an, E. Vieta, F. Colom et al., “Do cognitive
complaints in euthymic bipolar patients reﬂect objective
cognitive impairment?” Psychotherapy and Psychosomatics,
vol. 74, no. 5, pp. 295–302, 2005.
[153] O. Grynszpan, S. Perbal, A. Pelissolo et al., “Eﬃcacy
and speciﬁcity of computer-assisted cognitive remediation
in schizophrenia: a meta-analytical study,” Psychological
Medicine, vol. 41, no. 1, pp. 163–173, 2011.
[154] D. I. Velligan, R. S. Kern, and J. M. Gold, “Cognitive
rehabilitation for schizophrenia and the putative role of
motivation and expectancies,” Schizophrenia Bulletin, vol. 32,
no. 3, pp. 474–485, 2006.
[155] W. Fals-Stewart and W. K. K. Lam, “Computer-assisted
cognitive rehabilitation for the treatment of patients with
substance use disorders: a randomized clinical trial,” Exper-
imental and Clinical Psychopharmacology, vol. 18, no. 1, pp.
87–98, 2010.
[156] VA Connecticut Healthcare System. Cognitive Training to
EnhanceVAWorkOutcomes.In:clinicalTrials.gov.Bethesda,
Md, USA, National Library of Medicine (US), 2000,
http://clinicaltrials.gov/show/NCT00829400.
[157] North Shore Long Island Jewish Health System. Cogni-
tive Enhancement in Bipolar Disorder. ClinicalTrials.gov.
Bethesda, Md, USA, National Library of Medicine (US),
2000, http://clinicaltrials.gov/show/NCT00597896.
[158] F. Colom, E. Vieta, J. S´ anchez-Moreno et al., “Psychoeduca-
tion for bipolar II disorder: an exploratory, 5-year outcome
subanalysis,” Journal of Aﬀective Disorders, vol. 112, no. 1–3,
pp. 30–35, 2009.
[159] F. Colom, E. Vieta, J. S´ anchez-Moreno et al., “Group
psychoeducation for stabilised bipolar disorders: 5-Year
outcome of a randomised clinical trial,” British Journal of
Psychiatry, vol. 194, no. 3, pp. 260–265, 2009.
[160] E. Brohan, D. Gauci, N. Sartorius, and G. Thornicroft, “Self-
stigma, empowerment and perceived discrimination among
people with bipolar disorder or depression in 13 European
countries: the GAMIAN-Europe study,” Journal of Aﬀective
Disorders, vol. 129, no. 1–3, pp. 56–63, 2010.
[161] E. Brohan, M. Slade, S. Clement, and G. Thornicroft,
“Experiences of mental illness stigma, prejudice and discrim-
ination:areviewofmeasures,”BMCHealthServicesResearch,
vol. 10, article 80, 2010.